An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 3, 2009, Pages 753-762

  Mei, Li ^a   Zhang, Lixin ^b   Dai, Renke ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Antifungal effect; Beauvericin; Cytochrome P450; Inhibition; Pharmacokinetic

Indexed keywords

BEAUVERICIN; CYTOCHROME P450; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; ANTIFUNGAL AGENT; CYTOCHROME P450 INHIBITOR; DEPSIPEPTIDE; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; MASS SPECTROMETRY; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; MASS SPECTROMETRY; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SUBSTRATE SPECIFICITY;

EID: 70749135180     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802362041     Document Type: Article

References (24)

1. Plattner RD, Nelson PE. Production of beauvericin by a strain of Fusarium proliferatum isolated from Corn Fodder for Swine. Appl Environ Microbiol 1994;60:3894-3896.
2. Zhang LX, Yan KZ, Zhang Y, Huang R, Bian J, Zheng CS, Sun HX, Chen ZH, Sun N, An R, Min FG, Zhao WB, Zhuo Y, You JL, Song YJ, Yu ZY, Liu ZH, Yang KQ, Gao H, Dai HQ, Zhang XL,Wang J, Fu CZ, PeiG, Liu JT, Zhang S, Michael G, Jiang YY, Kuai J, Zhou GC, Chen XP. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. PNAS 2007;104:4606-4611.
3. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B,KaizerH, Shadduck RK, Shea TC, Stiff P, Friedman DJ. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.
4. Larocco MT, Burgert SJ. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 1997; 10:277-297.
5. Sanchez V, Vasquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervus MJ. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med 1993;94:577-582. (Pubitemid 23166702)
6. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
7. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-517.
8. Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, Craven PC, Stevens DA. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1997;31:1874-1878.
9. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King PS, Miwa G, Ni L, Kumar G, Mcleod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832.
10. Crespi CL, Stresser DM. Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Meth 2000;44:325-331.
11. Xia ZL, Ying JY, Sheng R, Zeng S, Hu YZ, Yao TW. In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography- mass spectrometry method. J Chromatogr B 2007;857:266-274.
12. Yao M, Zhu MS, Michael WS, Zhang HJ, Humphreys WG, Rodrigues AD, Dai R. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007;44:211-223.
13. Zhong DF, Zhang SQ, Sun L, Zhao XY. Metabolism of roxithromycin in phenobarbital-treated rat liver microsomes. Acta Pharmacol Sin 2002;23:455-460.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
15. Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: Screening with cDNA-expressed systems of the rat. Biochem Pharmacol 2002;63:889-896.
16. Obach SR, Reed-Hagen AE. Measurement of Michaelis Constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002;30:831-837.
17. Nath A, Atkins WM. A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metab Dispos 2006;34:1433-1435.
18. Segal IH. Enzyme kinetics. New York: Wiley-Interscience; 1975. p 957.
19. Chang TK, Chen J, Lee WB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: Evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001;299:874-882.
20. Zhang D, Zhu M, Humphreys WG. Drug metabolism in drug design and developmen. New Jersey: Wiley; 2007. p 513-543.
21. Rodriques D. Drug-drug interactions. New York: Marcel Dekker, Inc; 2002. p 217-293.
22. Lee JS, Obach RS, Fisher MB. Drug metabolizing enyzmes: Cytochrome P450 and other enzymes in drug discovery and development. New York: Fontis Media, Lausanne, Switzerland and Marcel Dekker; 2003. p 211-254.
23. Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearence: Time dependences in hepatocyte and microsomal incubations. Drug Metab Dispos 2004;32:973-982.
24. Kotegawa T, Laurijssens BE, Durol ALB, Greenblatt DJ. Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. Biopharm Drug Dispos 1999; 20:49-52.